Horizon Therapeutics logo

HZNP - Horizon Therapeutics Share Price

$93.18 -0.4  -0.4%

Last Trade - 6:55pm

Large Cap
Market Cap £15.05bn
Enterprise Value £14.28bn
Revenue £1.58bn
Position in Universe 569th / 6852
Unlock HZNP Revenue
Relative Strength (%)
1m -2.11%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -3.10%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
757 981.1 1,056 1,208 1,300 2,200 2,800 3,482 +23.8%
-31.0 +67.7 +39.2
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, HorizonTherapeutics PLC revenues increased 69% to $2.2B. Netincome decreased 32% to $389.8M. Revenues reflect Orphanand Rheumatology segment increase of 92% to $1.79B,Inflammation segment increase of 11% to $412.8M, Rest ofworld segment increase of 22% to $9.3M. Net income wasoffset by Sales and Marketing - Balancing value increase of37% to $847.8M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for HZNP
Graphical History


HZNP Revenue Unlock HZNP Revenue

Net Income

HZNP Net Income Unlock HZNP Revenue

Normalised EPS

HZNP Normalised EPS Unlock HZNP Revenue

PE Ratio Range

HZNP PE Ratio Range Unlock HZNP Revenue

Dividend Yield Range

HZNP Dividend Yield Range Unlock HZNP Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
HZNP EPS Forecasts Unlock HZNP Revenue
Profile Summary

Horizon Therapeutics plc, formerly Horizon Pharma plc, is a rare disease biopharmaceutical company. The Company is focused on researching, developing and commercializing medicines that address needs for people impacted by rare and rheumatic diseases. The Company markets approximately 10 medicines, of which 6 are for rare and rheumatic diseases. The Company's marketed medicines are ACTIMMUNE (interferon gamma-1b), BUPHENYL (sodium phenylbutyrate) Tablets and Powder, DUEXIS (ibuprofen/famotidine), KRYSTEXXA (pegloticase), PENNSAID (diclofenac sodium topical solution) 2% weight per weight (w/w), or PENNSAID 2%, PROCYSBI (cysteamine bitartrate) delayed-release capsules, QUINSAIR (aerosolized form of levofloxacin), RAVICTI (glycerol phenylbutyrate) Oral Liquid, RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium).

Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated December 20, 2011
Public Since August 11, 2010
No. of Shareholders: 9
No. of Employees: 1,395
Sector Healthcare
Industry Pharmaceuticals
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 224,074,399
Free Float (0.0%)
Eligible for
HZNP Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for HZNP
Upcoming Events for HZNP
Thursday 29th April, 2021
Horizon Therapeutics PLC Annual Shareholders Meeting
Friday 30th April, 2021 Estimate
Horizon Therapeutics PLC Annual Shareholders Meeting
Wednesday 5th May, 2021
Q1 2021 Horizon Therapeutics PLC Earnings Call
Wednesday 5th May, 2021
Q1 2021 Horizon Therapeutics PLC Earnings Release
Wednesday 4th August, 2021 Estimate
Q2 2021 Horizon Therapeutics PLC Earnings Release
Frequently Asked Questions for Horizon Therapeutics
What is the Horizon Therapeutics share price?

As of 6:55pm, shares in Horizon Therapeutics are trading at $93.18, giving the company a market capitalisation of £15.05bn. This share price information is delayed by 15 minutes.

How has the Horizon Therapeutics share price performed this year?

Shares in Horizon Therapeutics are currently trading at $93.18 and the price has moved by 0.187k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Horizon Therapeutics price has moved by 94.33% over the past year.

What are the analyst and broker recommendations for Horizon Therapeutics?

Of the analysts with advisory recommendations for Horizon Therapeutics, there are there are currently 6 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Horizon Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Horizon Therapeutics next release its financial results?

Horizon Therapeutics is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Horizon Therapeutics dividend yield?

Horizon Therapeutics does not currently pay a dividend.

Does Horizon Therapeutics pay a dividend?

Horizon Therapeutics does not currently pay a dividend.

When does Horizon Therapeutics next pay dividends?

Horizon Therapeutics does not currently pay a dividend.

How do I buy Horizon Therapeutics shares?

To buy shares in Horizon Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Horizon Therapeutics?

Shares in Horizon Therapeutics are currently trading at $93.18, giving the company a market capitalisation of £15.05bn.

Where are Horizon Therapeutics shares listed? Where are Horizon Therapeutics shares listed?

Here are the trading details for Horizon Therapeutics:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: HZNP
What kind of share is Horizon Therapeutics?

Based on an overall assessment of its quality, value and momentum, Horizon Therapeutics is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Horizon Therapeutics share price forecast 2021?

Shares in Horizon Therapeutics are currently priced at $93.18. At that level they are trading at 21.86% discount to the analyst consensus target price of 0.00.

Analysts covering Horizon Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of 3.628 for the next financial year.

How can I tell whether the Horizon Therapeutics share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Horizon Therapeutics. Over the past six months, the relative strength of its shares against the market has been -0.64%. At the current price of $93.18, shares in Horizon Therapeutics are trading at 21.36% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Horizon Therapeutics PE Ratio?

The Horizon Therapeutics PE ratio based on its reported earnings over the past 12 months is 43.24. The shares are currently trading at $93.18.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Horizon Therapeutics?

Horizon Therapeutics's management team is headed by:

William Daniel - IND
Michael Grey - LED
Jeffrey Himawan - IND
Gino Santini - IND
Timothy Walbert - CHM
Brian Beeler - EVP
Geoffrey Curtis - EVP
Paul Hoelscher - CFO
Barry Moze - EVP
Michael DesJardin - EVP
Vikram Karnani - EVP
Irina Konstantinovsky - CHO
Susan Mahony - IND
Jeffrey Kent - EVP
Daniel Camardo - EVP
Who are the major shareholders of Horizon Therapeutics?

Here are the top five shareholders of Horizon Therapeutics based on the size of their shareholding:

The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 8.89% (19.9m shares)
Fidelity Management & Research Company LLC Investment Advisor
Percentage owned: 5.82% (13.0m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 5.16% (11.6m shares)
Avoro Capital Advisors LLC Investment Advisor/Hedge Fund
Percentage owned: 4.02% (9.00m shares)
Janus Henderson Investors Investment Advisor/Hedge Fund
Percentage owned: 3.66% (8.19m shares)
Similar to HZNP
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.